Increased glycolytic substrate protection improves ischemic cardiac dysfunction and reduces injury

Early clinical trials of glucose-insulin-potassium for acute myocardial infarction were inconclusive. However, several recent placebo-controlled, prospective, randomized clinical trials of glucose-insulin-potassium for acute myocardial infarction or metabolic support during and after cardiac surgery have demonstrated its efficacy. These clinical results are supported by experimental studies that have shown a strong protective effect of increased glycolytic substrate on ischemic myocardium in concert with an improved bioenergetic status.